ALLERGAN USA, INC. — Lobbying Disclosure | Poliscope

ALLERGAN USA, INC.

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$37.2M

Filings

107

Firms Hired

Active Period

2001–2020

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2020	$1,310,000	2	1
2019	$2,880,000	4	1
2018	$3,090,000	9	2
2017	$2,860,000	6	2
2016	$4,490,000	7	1
2015	$4,580,000	8	2
2014	$2,010,000	8	2
2013	$2,271,590	9	3
2012	$2,870,000	10	2
2011	$2,220,000	8	2
2010	$1,960,000	9	2
2009	$1,130,000	6	2
2008	$1,010,390	6	1
2007	$1,400,000	3	1
2006	$440,000	1	1
2005	$800,000	2	1
2004	$860,000	3	1
2003	$240,000	1	1
2002	$400,000	2	1
2001	$420,000	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
ALLERGAN USA, INC.	$37,241,980	74
CAUTHEN FORBES & WILLIAMS	—	16
FORBES-TATE	—	11
SIXKILLER CONSULTING, LLC	—	2
J P FORD STRATEGIES, LLC	—	4

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	94
HOUSE OF REPRESENTATIVES	93
Food & Drug Administration (FDA)	30
Centers For Medicare and Medicaid Services (CMS)	24
Health & Human Services, Dept of (HHS)	14
Patent & Trademark Office (PTO)	14
Federal Communications Commission (FCC)	8
Office of Management & Budget (OMB)	8
Federal Trade Commission (FTC)	5
Natl Institutes of Health (NIH)	4
Veterans Affairs, Dept of (VA)	4
White House Office	3
Internal Revenue Service (IRS)	2
Medicare Payment Advisory Commission (MedPAC)	2
Treasury, Dept of	2
Centers For Disease Control & Prevention (CDC)	1
Commerce, Dept of (DOC)	1
UNDETERMINED	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medicare/Medicaid	Medicare/Medicaid	91
Health Issues	Health Issues	89
Copyright/Patent/Trademark	Copyright/Patent/Trademark	72
Budget/Appropriations	Budget/Appropriations	63
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	50
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	46
Pharmacy	Pharmacy	34
Telecommunications	Telecommunications	21
Trade (domestic/foreign)	Trade (domestic/foreign)	21
Labor Issues/Antitrust/Workplace	Labor Issues/Antitrust/Workplace	10
Foreign Relations	Foreign Relations	4
Disaster Planning/Emergencies	Disaster Planning/Emergencies	2
Accounting	Accounting	1
Indian/Native American Affairs	Indian/Native American Affairs	1
Manufacturing	Manufacturing	1
Consumer Issues/Safety/Products	Consumer Issues/Safety/Products	1
Alcohol and Drug Abuse	Alcohol and Drug Abuse	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3204113th Congress

Drug Quality and Security Act

2018 · first_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).

Client expense: $1,420,000 · Firm income: —

Matched citations: H.R. 3204

S. 1948115th Congress

A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents.

2017 · fourth_quarter · Firm: SIXKILLER CONSULTING, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S.1948, a bill to abrogate the sovereign immunity of Indian tribes.

Client expense: — · Firm income: $50,000

Matched citations: S.1948

H.R. 3204113th Congress

Drug Quality and Security Act

2017 · fourth_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).

Client expense: $480,000 · Firm income: —

Matched citations: H.R. 3204

H.R. 1115th Congress

An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.

2017 · fourth_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1 (tax policy including changes to corporate tax structure) Tax codes that ensure investment in research & development of novel treatments for patients.

Client expense: $480,000 · Firm income: —

Matched citations: H.R. 1

Show 21 more cited filings

S. 1948115th Congress

A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents.

2017 · fourth_quarter · Firm: SIXKILLER CONSULTING, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S.1948, a bill to abrogate the sovereign immunity of Indian tribes.

Client expense: — · Firm income: —

Matched citations: S.1948

H.R. 3204113th Congress

Drug Quality and Security Act

2017 · third_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).

Client expense: $860,000 · Firm income: —

Matched citations: H.R. 3204

H.R. 3204113th Congress

Drug Quality and Security Act

2017 · second_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).

Client expense: $320,000 · Firm income: —

Matched citations: H.R. 3204

H.R. 2646114th Congress

Helping Families in Mental Health Crisis Act of 2016

2016 · fourth_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.

Client expense: $490,000 · Firm income: —

Matched citations: H.R. 2646

S. 2680114th Congress

Mental Health Reform Act of 2016

2016 · fourth_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.

Client expense: $490,000 · Firm income: —

Matched citations: S. 2680

H.R. 2646114th Congress

Helping Families in Mental Health Crisis Act of 2016

2016 · fourth_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.

Client expense: $370,000 · Firm income: —

Matched citations: H.R. 2646

S. 2680114th Congress

Mental Health Reform Act of 2016

2016 · fourth_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.

Client expense: $370,000 · Firm income: —

Matched citations: S. 2680

H.R. 2646114th Congress

Helping Families in Mental Health Crisis Act of 2016

2016 · third_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.

Client expense: $850,000 · Firm income: —

Matched citations: H.R. 2646

S. 2680114th Congress

Mental Health Reform Act of 2016

2016 · third_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.

Client expense: $850,000 · Firm income: —

Matched citations: S. 2680

H.R. 2646114th Congress

Helping Families in Mental Health Crisis Act of 2016

2016 · fourth_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.

Client expense: $330,000 · Firm income: —

Matched citations: H.R. 2646

S. 2680114th Congress

Mental Health Reform Act of 2016

2016 · fourth_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.

Client expense: $330,000 · Firm income: —

Matched citations: S. 2680

H.R. 2646114th Congress

Helping Families in Mental Health Crisis Act of 2016

2016 · third_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.

Client expense: $820,000 · Firm income: —

Matched citations: H.R. 2646

S. 2680114th Congress

Mental Health Reform Act of 2016

2016 · third_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.

Client expense: $820,000 · Firm income: —

Matched citations: S. 2680

H.R. 2646114th Congress

Helping Families in Mental Health Crisis Act of 2016

2016 · second_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016.

Client expense: $860,000 · Firm income: —

Matched citations: H.R. 2646

S. 2680114th Congress

Mental Health Reform Act of 2016

2016 · second_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016.

Client expense: $860,000 · Firm income: —

Matched citations: S. 2680

H.R. 486113th Congress

Stop Tampering of Prescription Pills Act of 2013

2015 · second_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $2,500,000 · Firm income: —

Matched citations: H.R. 486

H.R. 672113th Congress

Prescription Drug Abuse Prevention and Treatment Act of 2013

2015 · second_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $2,500,000 · Firm income: —

Matched citations: H.R. 672

H.R. 1285114th Congress

Eliminating the Hidden Student Loan Tax Act

2015 · second_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $2,500,000 · Firm income: —

Matched citations: H.R. 1285

S. 214113th Congress

Preserve Access to Affordable Generics Act

2015 · second_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills

Client expense: $2,500,000 · Firm income: —

Matched citations: S. 214

S. 348114th Congress

PLANT Act

2015 · second_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $2,500,000 · Firm income: —

Matched citations: S. 348

S. 504114th Congress

Great Lakes Ecological and Economic Protection Act of 2015

2015 · second_quarter · Firm: ALLERGAN USA, INC.

Open original LDA filing ↗

Cited source text and reported amounts

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $2,500,000 · Firm income: —

Matched citations: S. 504

Source: Senate LDA